Neuroone Medical Technologies closed at $1.70 (+3.03%) on July 30, and extended its rally in after-hours trading to $1.80 (+5.88% from today's close). - The surge was primarily driven by encouraging physician-reported outcomes from a Mayo Clinic study on the company's brain ablation device, showing meaningful seizure reduction for epilepsy patients. - This follows the official announcement of the positive data on July 28, 2026.